EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Therapeutic Potential of Adipose-Derived Mesenchymal Stem Cells Transplantation into the Lacrimal Gland in Patients with Sjögren Syndrome

Mojtaba Mohammadpour, Shahrokh Ramin, Ramin Sarrami-Forooshani, Somayeh Ghorbani, Masoumeh Ahadi, Iman Ansari, Akmal K Matkarimov, Hassan Sanati, Ali Abbasi

Korean Journal of Ophthalmology · 2026

DOI: 10.3341/kjo.2025.0095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Korean Journal of Ophthalmology, 2026. Verfasst von Mojtaba Mohammadpour und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Optometry, School of Rehabilitation Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Lacrimal Apparatus, Mesenchymal Stem Cell Transplantation, Adipose Tissue. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shahid Beheshti University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study evaluated the feasibility and effectiveness of autologous adipose-derived mesenchymal stem cell (ASC) transplantation into the lacrimal gland for treating aqueous-deficient dry eye disease (DED) associated with Sjögren syndrome.

Methods

Patients with Sjögren syndrome–related DED underwent autologous adipose tissue harvest via liposuction. ASCs were isolated, cultured, and injected into the lacrimal gland (volume ≤50% of estimated gland volume). Clinical evaluations— including Ocular Surface Disease Index (OSDI), tear osmolarity, tear film breakup time (TBUT), Oxford corneal staining, and Schirmer test I—were conducted at 1-, 4-, 16-, and 24-weeks after injection. Visual quality assessments included contrast sensitivity and higher-order aberrations (HOAs).

Results

Six patients (mean age 56.1 ± 7.2 years) completed the study. Mean OSDI scores significantly decreased from 48.6 ± 8.4 to 28 ± 2.1. TBUT improved in both eyes (right, 3.3 ± 1.0 to 5.6 ± 1.2 seconds; left, 3.6 ± 1.0 to 6.1 ± 1.6 seconds). Schirmer test I values increased (right, 4.1 ± 0.7 to 7.8 ± 0.7 mm; left, 4.0 ± 0.6 to 7.6 ± 0.5 mm). Oxford staining scores decreased (right, 1.6 ± 0.5 to 0.67 ± 0.2; left, 1.3 ± 0.5 to 0.67 ± 0.2). Tear osmolarity also improved (right, 311.6 ± 6.1 to 299.1 ± 5.8 mOsm/L; left, 309 ± 7.6 to 298.3 ± 7 mOsm/L). HOAs were reduced in one eye. No significant change in contrast sensitivity or visual acuity was observed. No adverse events were reported.

Conclusions

Autologous ASC transplantation into the lacrimal gland appears to be a safe and promising therapeutic option for aqueous-deficient DED in Sjögren syndrome, offering significant improvement in both objective measures and patient-reported symptoms over a 6-month period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sjogren's SyndromeLacrimal ApparatusMesenchymal Stem Cell TransplantationAdipose TissueDry Eye SyndromesHumansMiddle AgedFemaleMaleTearsTransplantation, AutologousFollow-Up StudiesTreatment OutcomeAdultAged

Stichwörter der Autor:innen

Adipose-derived mesenchymal stem cellsDry eye syndromesLacrimal glandMesenchymal stem cell transplantationSjogren’s syndrome

Autor:innen und Institutionen

  • Department of Optometry, School of Rehabilitation Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Advanced Therapy Medicinal Product (ATMP), Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran.
  • Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
  • Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Dr. Maksudova Innovation Clinic at "BL LAZEROPTIKA" JV LLC, Tashkent, Uzbekistan.
  • EvomedScience Co., Marburg, Germany.

Förderung

  • Shahid Beheshti University of Medical Sciences

Zitieren

APA

Mohammadpour, M., Ramin, S., Sarrami-Forooshani, R., Ghorbani, S., Ahadi, M., Ansari, I., Matkarimov, A. K., Sanati, H., & Abbasi, A. (2026). Therapeutic Potential of Adipose-Derived Mesenchymal Stem Cells Transplantation into the Lacrimal Gland in Patients with Sjögren Syndrome. Korean Journal of Ophthalmology. https://doi.org/10.3341/kjo.2025.0095

Vancouver

Mohammadpour M, Ramin S, Sarrami-Forooshani R, Ghorbani S, Ahadi M, Ansari I, et al. Therapeutic Potential of Adipose-Derived Mesenchymal Stem Cells Transplantation into the Lacrimal Gland in Patients with Sjögren Syndrome. Korean Journal of Ophthalmology. 2026. doi:10.3341/kjo.2025.0095

BibTeX
@article{Mohammadpour2026,
  author = {Mohammadpour, Mojtaba and Ramin, Shahrokh and Sarrami-Forooshani, Ramin and Ghorbani, Somayeh and Ahadi, Masoumeh and Ansari, Iman and Matkarimov, Akmal K and Sanati, Hassan and Abbasi, Ali},
  title = {Therapeutic Potential of Adipose-Derived Mesenchymal Stem Cells Transplantation into the Lacrimal Gland in Patients with Sjögren Syndrome},
  journal = {Korean Journal of Ophthalmology},
  year = {2026},
  doi = {10.3341/kjo.2025.0095}
}
Kostenlos starten →